SLC16A2 and cancer: Of the TKIs tested, dasatinib was selectively cytotoxic to HPV+, but not HPV- HNSCC cell lines (Supplementary Figure S2), suggesting that it could be used as a treatment for HPV+ HNSCC that expresses high levels of SLC16A2. A flavonoid, silychristin, also inhibits SLC16A2 [45], but has not been studied in cancer models.